Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients with Bietti Crystalline Dystrophy

Key Inclusion Criteria:

1. Able to provide informed consent and comply with requirements of the study;

2. ≥18 years and <70 years of age;

3. Confirmed diagnosis of Bietti Crystalline Dystrophy and molecular diagnosis ofCYP4V2 mutations (homozygotes or compound heterozygotes);

4. Hand Motion ≤ BCVA ≤ 60 ETDRS letters in the study eye;

Key Exclusion Criteria:

1. Have insufficient viable retinal photoreceptor cells based on investigator'sdecision;

2. Have current ocular or periocular infections, or endophthalmitis;

3. Have any significant ocular disease/disorder other than BCD, including age-relatedmacular degeneration, diabetic retinopathy, optic neuropathy, significant lensopacity, glaucoma, uveitis, retinal detachment, etc;

4. Have intraocular surgery history except cataract surgery in the study eye;

5. Have or potentially require of systemic medications that may cause eye injure;

6. Have contraindications for corticosteroids or immunosuppressant;

7. Unwilling or unable to have the planned follow-up;

8. Abnormal coagulation function or other clinically significant abnormal laboratoryresults;

9. Have malignancies or history of malignancies;

10. History of immunodeficiency (acquired or congenital); Other protocol definedInclusion/Exclusion criteria may apply.